Kinarus Therapeutics : July 2023 Investor Presentation

Corporate deck

July 2023

Disclaimer

Kinarus AG, www.kinarus.com

This Company Presentation and supporting material (together the "Material") with regard to Kinarus AG ("Kinarus" or the "Company") is based on information provided by the Company. It may only be used to the benefit of and the internal use of the receiver. Kinarus holds all rights related to the Material.

This Company Presentation is not to be considered similar to a prospectus and does not constitute an offer or the solicitation of an offer for the sale or purchase or licensing of any assets or shares of Kinarus. Neither this Company Presentation nor the information contained herein shall form the basis of or constitute any contract or binding offer.

The Material is disclosed to the interested party as confidential information. The interested party shall not distribute Material beyond any of its officers, employees, shareholders or other representatives without the prior written authorization of the Company.

The Material has been prepared for informational purposes. Any forward looking statement, projections of financial or operating results are based on estimates by Kinarus, and there can be no assurance that such results will be realized.

Kinarus makes no express or implied representation or warranty as to the accuracy or completeness of the information contained herein. Kinarus expressly disclaim any and all liability, which may be based on such information, errors therein or omissions therefrom.

In furnishing the Material, Kinarus dies not undertake any obligation to provide interested parties with access to any additional information, to update the Material, or to correct any inaccuracies. This Material shall not constitute an indication that there has been no change in the business or affairs of the Company since the date thereof.

By retaining this Company Presentation, the interested party acknowledges that it has read, understood and accepted the terms of this disclaimer.

This disclaimer shall be governed by and construed in accordance with the laws of Switzerland.

confidential - not for further distribution	2

Executive Summary

Kinarus AG, www.kinarus.com

• Kinarus is a biotech company developing a combination therapy for Idiopathic Pulmonary Fibrosis, retinal, and autoimmune disorders
• Key asset - KIN001 - p38 MAPK inhibitor pamapimod (Roche) + pioglitazone (marketed)
• KIN001 unlocks the broad potential of p38 MAPK inhibition, a central pathway in inflammatory and fibrotic diseases
• Based on its own research, Kinarus has positioned KIN001 in several high value indications
• Prepared to start robust phase 2 clinical studies
• Key IP protection to at least 2037, worldwide rights from Roche
• Repositioning strategy of late-stage assets - decreased clinical risk, technical risk, faster to market, multiple shots on goal
• Experienced management team - proven track record to initiate and conduct comprehensive clinical studies with small team in a cost-effective approach

confidential - not for further distribution	3

Experienced Leadership

We are drug developers

Kinarus AG, www.kinarus.com

Dr. Alexander Bausch

Chief Executive Officer

Dr. Matthew Wright

Chief Operations Officer

Head of Research

Dr. Thierry Fumeaux

Chief Medical Officer

Claudia Berger

Chief Clinical Dev. Officer

• Direct know-how and in-depth expertise with Kinarus' therapeutic targets and disease indications
• Established relationships with leading clinical experts

confidential - not for further distribution

4

Kinarus AG, www.kinarus.com

Pamapimod

Clinical-stage p38 MAPK inhibitor in-licensed from Roche

The Asset

• p38 MAPK inhibitors were actively under development 2005-2010 for autoimmune indications (e.g. Rheumatoid Arthritis)
• Pamapimod was discovered and developed by Roche
• • Safe in preclinical and clinical testing
  • Engages with target - demonstrated effects on clinical biomarkers

The Problem

• Relatively short-lived efficacy (see graph)
• • Compensatory cellular bypass mechanisms
• Roche discontinued pamapimod development in 2007

The Kinarus Solution

• • Pamapimod + pioglitazone = KIN001
  • • Pioglitazone blocks compensatory mechanisms
    • Prolongs pamapimod's efficacy without compromising safety
    • Novel intellectual property (composition of matter protection until 2037)
• KIN001 is a Phase 2-ready,patent-protected innovative drug candidate that unlocks the value of p38 MAPK inhibition

confidential - not for further distribution

5